Global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market, By Type (IgG, IgA, and IgM), By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 43,205.8 million in 2020, and is expected to exhibit a CAGR of 12.7% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Approval of new intravenous human immunoglobulin products by regulatory authorities are expected to drive the growth of the human immunoglobulin (ph4) for intravenous injection (COVID-19) market during the forecast period. For instance, on March 2019, CSL Behring, a manufacturer of plasma-derived and recombinant therapeutics, received approval from Japan’s Ministry of Health, Labour and Welfare Privigen, an intravenous immunoglobulin (IVIG), for treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Browse 27 Market Data Tables and 26 Figures spread through 201 Pages and in-depth TOC on “Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market”- Global Forecast to 2027, by Type (IgG, IgA, and IgM), by Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL), and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) market, click the link below:

https://www.coherentmarketinsights.com/market-insight/human-immunoglobulin-ph4-for-intravenous-injection-market-3790

Key players are accelerating their research and development activities in order to develop a treatment for the COVID-19 disease which is expected to boost the market growth during the forecast period. For instance, March 4, 2020, Takeda Pharmaceutical Company Limited informed the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), TAK-888, to treat patients with COVID-19.

Furthermore, on April 6, 2020, major market players such as Biotest Pharmaceuticals Corporation, BPL, LFB, and Octapharma AG joined the alliance formed by CSL Behring and Takeda Pharmaceutical Company Limited for the development of plasma-derived therapy to treat COVID-19.

Key Takeaways of the Global Human Immunoglobulin (ph4) for Intravenous injection (COVID-19) Market:

  • The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is expected to exhibit a CAGR of 12.7% during the forecast period owing to the viral disease outbreak. According to the World Health Organization, around 464,212 cases of coronavirus disease were reported in Europe on April 1, 2020.
  • Among Type, the IgG segment held a higher market share in 2019 owing to an increase in product approvals. For instance, on April 2019, ADMA Biologics, Inc. received approval from the U.S. Food and Drug Administration (FDA) for ASCENIV, human immune globulin intravenous (IgG) solution, for treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to 17 years of age).
  • Among disease indication, the primary immunodeficiency disease segment held a higher market share in 2019 owing to the growing prevalence of primary immunodeficiency diseases. For instance, United Kingdom Primary Immunodeficiency (UKPID) Registry estimated that around 4758 people were suffering from primary immunodeficiency disease in UK in 2017. However, due to coronavirus outbreak, demand for immunoglobulin products is expected to increase. As a result, the COVID-19 segment is expected to hold the highest market share in 2020.
  • Companies operating in the global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) market are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner